Hepatic impairment No dose adjustment is needed in patients with mild or average (Baby-Pugh A or B) hepatic impairment (see area 5.two). Exposure to midostaurin and its Lively metabolite CGP62221 is considerably reduced in sufferers with severe hepatic impairment than that in people with normal hepatic perform (see portion 5. https://miriama963nrv5.luwebs.com/profile